Fibrinolytic therapy for thrombosis in cardiac valvular prosthesis short and long term results

Abstract

Objective -To assess the short-and long-term results of the use of streptokinase (SK) for the treatment of thromboses in cardiac valvular prostheses. Methods -

Thrombolytic therapy or surgery for valve prosthesis thrombosis: systematic review and meta‐analysis

“…. Forty‐eight studies were included ( n = 2239) (Table ). There were 27 studies or study arms evaluating cohorts of patients that underwent surgery for prosthetic heart valve thrombosis ; mean age 45.2 years, 38.9% were male.…”

“…There were 27 studies or study arms evaluating cohorts of patients that underwent surgery for prosthetic heart valve thrombosis ; mean age 45.2 years, 38.9% were male. There were 26 studies or study arms evaluating cohorts of patients that received thrombolytic therapy ; mean age 43.8 years, 36.3% were male. Analysis of study quality by the Newcastle‐Ottawa Scale varied from 4 to 6 stars (mean 5.5).…”

“…There were 27 studies or study arms evaluating cohorts of patients that underwent surgery for prosthetic heart valve thrombosis [17][18][19][20][21][23][24][25][26][27]30,31,33,35,36,39,42,43,[47][48][49][50]53,55,[57][58][59]; mean age 45.2 years, 38.9% were male. There were 26 studies or study arms evaluating cohorts of patients that received thrombolytic therapy [2,16,19,22,[27][28][29]31,32,34,37,38,40,41,[44][45][46][47]49,51,52,54,56,…”

Mitral valve replacement at Tygerberg Hospital: a 5 year follow-up

“…The results after a 42 month period show a 5.8% mortality, 67% free from rethrombosis, and 17.6% embolic complications in some studies. (15) At Tygerberg Hospital a study was done that documented the diagnosis and management of prosthetic valve obstruction. (24) A total of 6 patients received thrombolitic therapy and 4 of these patients were considered too ill for surgery.…”

O uso da estreptoquinase no tratamento da oclusão arterial aguda pós-cateterização da artéria femoral em crianças com menos de 10 kg

“…Alguns autores utilizaram fibrinolíticos, em altas doses, por via endovenosa 29,[35][36][37][38] , ou em baixas doses via intra-arterial, com auxílio de 21 demonstraram uma diminuição do tempo, em relação aos trabalhos anteriores, de 5 horas. Já em relação ao tempo de uso da heparina, no GH, ele foi de 88 horas, e o término da infusão ocorreu quando se obteve a melhora da perfusão e não o retorno do pulso, motivo pelo qual apresentou um tempo alto de uso da medicação.…”